-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.ISIN US04685N1037-
ATHENEX INCBörse Börse BerlinSymbol 2MT
-
ATHENEX INCBörse Gettex System der Börse MünchenSymbol 2MT
-
ATHENEX INCBörse Börse DüsseldorfSymbol 2MT
-
ATHENEX INCBörse Börse FrankfurtSymbol 2MT
-
ATHENEX INCBörse Börse MünchenSymbol 2MT
-
ATHENEX INCBörse Tradegate System der Deutsche Börse AG (60%)Symbol 2MT
-
ATHENEX INCBörse Börse StuttgartSymbol 2MT
-
ATHENEX INCBörse Quotrix System der Börse DüsseldorfSymbol 2MT
-
ISIN US04685N1037 WKN: A2DTE9Symbol ATNX
-
EUR
-
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.246.078.336 oder 370.000.000
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
574 oder 652 Mitarbeiter
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 4,64 USD -3,33%
Portrait der Athenex Aktie
Das Unternehmen Athenex, Inc aus USA beschäftigt 613 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharma tätig.
Das Unternehmen Athenex, Inc ist nur in 5 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter iShares Nasdaq US Biotechnology UCITS ETF gewichtet Athenex mit 0,03% im ETF.
5 ETFs die in Athenex investieren
Dir gefallen die Informationen zu Athenex?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Athenex?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Dir gefallen die Informationen zu Athenex?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Dir gefallen die Informationen zu Athenex?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
22 News & Informationen zur Athenex Aktie
Athenex: Is This Stock A Buy, Sell, Or Hold? (NASDAQ:ATNX)
Athenex is a biopharmaceutical company developing and commercializing next-generation drugs for treating cancers. See if ATNX stock is a buy, sell, or hold.
Ziopharm Oncology : Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions (Form 8-K)
Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions
Mr. Boyle brings over 20 years of executive… | August 30, 2021
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc. (NYSE: BIO) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) Johnson & Johnson (NYSE: JNJ) Laboratory Corporation of America Holdings (NYSE: LH) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) NanoVibronix, Inc. (NASDAQ: NAOV) (announced intention to enter over-
Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2021 Results – Earnings Call Transcript
Athenix, Inc. (NASDAQ:ATNX) Q2 2021 Earnings Conference Call August 5, 2021 08:00 AM ET Company Participants Tim McCarthy – LifeSci Advisors Johnson Lau – Chief Executive Officer Jeff…
Athenex, inc (ATNX) Q2 2021 Earnings Call Transcript
ATNX earnings call for the period ending June 30, 2021.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows.
Areas of Interest: The largest company in terms of market cap to …
Athenex EPS beats by $0.08, misses on revenue (NASDAQ:ATNX)
Athenex (ATNX): Q2 GAAP EPS of -$0.33 beats by $0.08.Revenue of $21.92M (-45.4% Y/Y) misses by $1.52M.Press Release
Athenex Provides Second Quarter 2021 Corporate and Financial Update
Updated investors on FDA Type A Meeting for oral paclitaxel Klisyri® approved by the European Commission in July 2021 KUR-501 GD2 CAR-NKT Phase 1 data in…
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of …
Athenex Announces Additional Licensing Agreements for Tirbanibulin
Athenex Announces Additional Licensing Agreements for Tirbanibulin
Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada
GlobeNewswire
July 26, 2021
BUFFALO, N.Y., July 26, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for…
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021
GlobeNewswire
July 22, 2021
BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and…
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.
Hedge Funds Have Never Been This Bullish On Kirkland’s, Inc. (KIRK)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact,…
Pharmaceutical Executive® APEX Awards Announces 2021 Finalists
/PRNewswire/ — Pharmaceutical Executive®, a leading multimedia platform for industry leaders to exchange experiences and insights about innovative business…
Pharmaceutical Executive® APEX Awards Announces 2021 Finalists
CRANBURY, N.J., July 8, 2021 /PRNewswire/ — Pharmaceutical Executive®, a leading multimedia platform for industry leaders to exchange experiences and
2 Falling Knives to Catch
GuruFocus Article or News written by Alberto Abaterusso and the topic is about: Athenex and Bellerophon Therapeutics have declined more than 59% over the past 52 weeks
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
GlobeNewswire
July 06, 2021
BUFFALO, N.Y., July 06, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the…
ATNX SHAREHOLDER DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.
NEW YORK, April 13, 2021 — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class…
Top Insider Buys Highlight for the Week of April 9
Top Insider Buys Highlight for the Week of April 9, release date:Apr 11, 2021
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important May 3 Deadline – ATNX
NEW YORK, April 10, 2021 — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. between August 7, 2019 and February 26, 2021,…
CEO Dr. Johnson Lau Contracts COVID-19
CEO Dr. Johnson Lau Contracts COVID-19
GlobeNewswire
January 08, 2021
BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr….
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
January 05, 2021
BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it…